The use of androgen suppression therapy (AST) in prostate cancer for low-risk cases declined following a decrease in physician reimbursement, according to a study published online TK in The Journal of the National Cancer Institute. However, the indicated use of AST for metastatic disease in the palliative setting did not decline in the same period. [...]
In the December 1 issue of JAMA, a study concluded that an active surveillance strategy for prostate cancer detection in male adults 65 years of age resulted in better quality of life measurements. 2009 saw roughly 192,000 men diagnosed with prostate cancer in the U.S. Out of this group, 70% will be said to have [...]
Two Vancouver researchers are tackling the deadliest forms of prostate cancer, the most commonly diagnosed male cancer in Canada, using a brand new field of genomics called computational chemogenomics. This new approach uses computer modeling in virtual 3D to predict how different chemicals or drugs will affect cancer tumours. The project, titled “Methods of Chemical [...]
The results of a recent Phase 3 study, known as study COU-AA-301, was able to successfully demonstrate the efficacy of a new investigational agent in the treatment of patients suffering from metastatic advanced prostate cancer, which is also known as Castration Resistant Prostate Cancer (CRPC). This new agent is biraterone acetate, and it proved to [...]
